Esperion Therapeutics ESPR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's operating cash flow?
- Esperion Therapeutics (ESPR) reported operating cash flow of -$27.72M in Q1 2026.
- How has Esperion Therapeutics's operating cash flow changed year-over-year?
- Esperion Therapeutics's operating cash flow decreased by 22.5% year-over-year, from -$22.63M to -$27.72M.
- What is the long-term trend for Esperion Therapeutics's operating cash flow?
- Over 2 years (2021 to 2023), Esperion Therapeutics's operating cash flow has grown at a -28.3% compound annual growth rate (CAGR), from -$263.81M to -$135.49M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.